[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100366498":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":44,"collaborators":7,"id":46,"slug":7,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":7,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":58,"studyType":59,"phases":7,"briefSummary":60,"conditions":61,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Immunis.AI","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Subtraction Normalized Expression of Phagocytes Blood Test","Non-invasive blood based immunogenomic assay that targets RNA sequencing to identify disease and disease aggressiveness",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Jessica DeHart","CONTACT","619-316-1416","jessica.dehart@oncocellmdx.com",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Comprehensive Urology","RECRUITING","Royal Oak","Michigan","48197","United States",{"type":28,"coordinates":29},"Point",[30,31],-83.14465,42.48948,{"lat":31,"lon":30},[34,38,41],{"name":35,"role":16,"phone":36,"phoneExt":7,"email":37},"Bridget Makhlouf","248-336-1080","bmakhlouf@urologist.org",{"name":39,"role":16,"phone":36,"phoneExt":7,"email":40},"Patrick Keating","pkeating@urologist.org",{"name":42,"role":43,"phone":7,"phoneExt":7,"email":7},"Howard Korman, MD","PRINCIPAL_INVESTIGATOR",{"type":45,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100366498",false,"NCT04052048","Active Surveillance SNEP Assay Registry Trial for Prostate Cancer","A Multi-center, Prospective Active Surveillance Registry Trial Assessing the Performance of a Non-invasive Immunogenomic Blood Test for Indolent Prostate Cancer Disease Management.","Inclusion Criteria\n\n* Men between 40-80 of age with at least a 10-year life expectancy\n* All active surveillance protocols are accepted\n* No PSA limits\n\nCategory 1:\n\n* Patient is currently on active surveillance with only ONE previous low grade prostate biopsy.\n* Patient must already be scheduled for their 1st annual biopsy under their active surveillance protocol within 90 days of enrollment date.\n\nCategory 2:\n\n• Patient is recently diagnosed with low grade prostate cancer but has decided against active surveillance and is scheduled for radical prostatectomy within 90 days of enrollment date.\n\nExclusion Criteria:\n\nMen on watchful waiting i.e. those with less than 10-year life expectancy with no intent for curative therapy\n\n* Men with symptoms or rising PSA who have not been proven to have cancer by tissue biopsy i.e. men with only negative prostate biopsies.\n* Patients with a history of a different cancer (except basal cell carcinoma)","MALE","40 Years","80 Years",{"count":56,"type":57},2000,"ESTIMATED","10 Years","OBSERVATIONAL","A multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.",[62],"Prostate Cancer Aggressiveness","2026-03-29",{"date":65,"type":66},"2026-04-02","ACTUAL",{"date":68,"type":66},"2019-09-09",{"date":70,"type":57},"2029-09-30",{"name":5,"class":6},1]